Identification and analysis of mutations in the katG gene in multidrug-resistant Mycobacterium tuberculosis clinical isolates by Jagielski, Tomasz et al.
www.pneumonologia.viamedica.pl
PRACA ORYGINALNA
298
Address for correspondence: Tomasz Jagielski, PhD, Department of Applied Microbiology, Institute of Microbiology, Faculty of Biology, University of Warsaw;  
ul. I. Miecznikowa 1, 02–096 Warszawa. Tel.: +48 22 55 41 312; Fax: +48 22 55 41 402, e-mail: t.jagielski@biol.uw.edu.pl
Praca wpłynęła do Redakcji: 14.09.2012
Copyright © 2013 PTChP
ISSN 0867–7077
Tomasz Jagielski1, Magdalena Grzeszczuk1, Michał Kamiński1, Katarzyna Roeske1,  
Agnieszka Napiórkowska2, Radosław Stachowiak1, Ewa Augustynowicz-Kopeć2,  
Zofia Zwolska2, Jacek Bielecki1
1Department of Applied Microbiology, Institute of Microbiology, Faculty of Biology, University of Warsaw
Head: Prof. J. Bielecki, PhD
2Department of Microbiology, National Tuberculosis and Lung Diseases Research Institute, Warsaw
Head: Prof. E. Augustynowicz-Kopeć, PhD
Identification and analysis of mutations in the katG gene in 
multidrug-resistant Mycobacterium tuberculosis clinical isolates
Identyfikacja i analiza mutacji w genie katG w szczepach klinicznych 
Mycobacterium tuberculosis o wielolekooporności typu MDR
This study was financed by the Ministry of Science and Higher Education. “Iuventus Plus” grant. (Project No. IP2011018771)
Abstract
Introduction: A major role in the development of resistance of Mycobacterium tuberculosis to isoniazid (INH) is attributed to 
mutations in the katG gene coding for the catalase/peroxidase, an enzyme required for obtaining a pharmacologically active form 
of the drug. Analysis of mutations in the katG gene in M. tuberculosis strains may contribute to the development of reliable and 
rapid tests for detection of INH resistance.
The aim of the study was to identify and characterize mutations in the katG gene in multidrug-resistant M. tuberculosis clinical isolates.
Material and methods: The study included 46 strains of M. tuberculosis, recovered from MDR-TB patients in Poland 
in 2004. Mutations in the katG gene were detected by comparing DNA sequences with the corresponding sequence of 
a wild-type reference laboratory  strain (M. tuberculosis H37Rv). The obtained results were interpreted in the context of MIC 
values of INH and catalase activity of the strains tested.
Results: A total of 43 (93%) strains contained mutations in the katG gene. The most frequently observed were mutations 
at codon 315, found in 34 (74%) strains. Mutations at other codons were rare: 4 strains contained mutations at codon 463, 
2 at codon 131 and another 2 at codon 234. Mutations at codons 68, 91, 101, 126, 128 and 194 were found in single strains 
only. Two strains, for which no mutations at codon 315 of the katG gene were identified, had a unique translation termination 
mutation, which would invariably result in polypeptide truncation leading to the generation of dysfunctional catalase poly-
peptides. Both these strains presented the highest MIC values for INH (80 and 100 µg/mL) and showed a complete loss of 
catalase activity. For the remaining 41 strains with katG mutations, the MICs of INH were within the range 0.2–10 µg/mL. 
Thirty-six (88%) of those strains retained their catalase activity.
Conclusions: Mutations at codon 315 within the katG gene, depending on their type might be useful for the prediction of INH 
resistance. Whereas the missense mutations do not affect the catalase activity or the level of INH resistance, the nonsense 
mutations result in high-level resistance to INH and a total loss of catalase activity.
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Streszczenie
Wstęp: Główną rolę w kształtowaniu oporności prątków gruźlicy (Mycobacterium tuberculosis) na izoniazyd (INH) przypisuje 
się mutacjom w genie katG kodującym białko katalazy/peroksydazy, enzym niezbędny do otrzymania aktywnej farmako-
logicznie formy leku. Analiza występowania mutacji w genie katG w szczepach M. tuberculosis może być podstawą dla 
opracowania wiarygodnych i szybkich testów wykrywania INH-oporności.
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Introduction
Tuberculosis (TB) is still one of the greatest 
threats to human health in the contemporary 
world. It is estimated that 1/3 of the human po-
pulation (more than 2 billion people) is infected 
with Mycobacterium tuberculosis. About 9 million 
new TB cases and 2 million deaths from the dise-
ase are noted each year [1]. The biggest challenge 
for a control and treatment system of TB is mul-
tidrug resistance of Mycobacterium tuberculosis. 
The multidrug resistance (MDR), i.e. resistance 
of mycobacteria to at least isoniazid (INH) and 
rifampicin (RMP), which are key drugs used in 
anti-TB therapy, is of crucial importance. It is esti-
mated that MDR-TB constitutes about 5% of all TB 
cases in the world. In Poland multidrug resistance 
concerns almost exclusively previously treated 
patients. The proportion of MDR-TB cases in this 
group of patients is about 8% [2].
A significant parameter, which describes the 
phenotype of drug-resistant strains of M. tuber-
culosis, including MDR strains, is the enzymatic 
activity of the catalase-peroxidase system. In the 
middle of the previous century it was shown that 
many INH-resistant strains are characterized by 
a partial or complete loss of catalase and peroxi-
dase activity [3–5]. This phenomenon has been 
used for diagnostic purposes. The examination of 
catalase activity has become an easy and rapid test 
that allows the susceptibility of clinical isolates to 
INH to be asessed.
Genetic research conducted in the early 1990s 
has been of vital importance in explaining the 
Celem pracy jest dentyfikacja i charakterystyka mutacji w genie katG w szczepach klinicznych M. tuberculosis o wieloleko-
oporności typu MDR.
Materiał i metody: Badanie objęło 46 szczepów wyizolowanych od chorych na gruźlicę MDR w Polsce w 2004 roku. Mutacje 
wykrywano, analizując sekwencje genu katG (2 223 pz) w porównaniu z sekwencją genu katG w szczepie M. tuberculosis 
H37Rv. Wyniki sekwencjonowania interpretowano w kontekście miana oporności na INH oraz aktywności katalazowej ba-
danych szczepów.
Wyniki: Mutacje w genie katG wykryto w 43 (93%) szczepach. Najczęściej obserwowaną była mutacja w kodonie 315, którą 
stwierdzono w 34 (74%) szczepach. Mutacje w innych kodonach występowały znacznie rzadziej; w 4 szczepach wykryto 
zmianę w kodonie 463, w 2 — w kodonie 131, a w innych 2 — w kodonie 234. Mutacje w kodonach 68, 91, 101, 126, 128 
i 194 dotyczyły pojedynczych szczepów.
W 2 szczepach wykryto pojedyncze mutacje typu nonsens, które, wprowadzając przedwczesne kodony terminacji transla-
cji, powodowały powstanie skróconego, niefunkcjonalnego białka katalazy. Szczepy te charakteryzowały się najwyższym 
mianem oporności na INH (MIC = 80 i 100 µg/ml) oraz całkowitą utratą aktywności katalazy. Dla pozostałych 41 szczepów 
niosących mutacje w genie katG, wartości MIC INH mieściły się w zakresie 0.2–10 µg/ml. Trzydzieści sześć (88%) spośród 
tych szczepów miało dodatni odczyn katalazy.
Wnioski: Rodzaj mutacji w kodonie 315 genu katG może służyć jako czynnik predykcyjny oporności na INH. Mutacje typu 
missens nie wpływają na aktywność katalazy oraz miano oporności na INH. Mutacje typu nonsens skutkują wysokim mianem 
INH-oporności oraz utratą aktywności katalazy.
Słowa kluczowe: analiza sekwencyjna, gruźlica, katG, mutacje, Mycobacterium tuberculosis, oporność typu MDR
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relation between catalase activity of mycobacteria 
and their resistance to INH. Zhang et al. proved 
that transformation of the INH-resistant strains 
of Mycobacterium smegmatis and M. tuberculosis, 
made with the help of the functional katG gene 
coding for catalase-peroxidase protein (KatG), 
restored these strains’ sensitivity to INH [6, 7]. 
Hence it has been proved that KatG plays a major 
role in the biological activity of INH and the con-
ditions the susceptibility of mycobacteria to this 
drug. However, the molecular mechanisms behind 
the INH activity are still unknown. Generally, it is 
assumed that INH is a prodrug, which after pene-
trating into the pathogen’s cell is oxidized — in the 
reaction catalysed by KatG — to pharmacologically 
active derivatives. Then they form adducts with 
molecules of the NAD+ or NADP+ coenzyme. 
These adducts operate as inhibitors of the enzyme 
participating in the biosynthesis of nucleic acids 
and mycolic acids, the latter being constituents of 
the mycobacterial cell wall [8].
The katG gene deletion observed in some 
INH-resistant strains has proven to be the main 
mechanism of resistance to INH. This hypothesis 
has not been confirmed by numerous subsequent 
studies. They have shown that a complete katG 
gene deletion occurs rarely and usually concerns 
strains with a high level of INH resistance (MIC > 
5 μg/mL) [9–12]. Currently it is considered that the 
main role in developing INH resistance is played 
by spontaneous mutations in the katG gene. They 
are usually single point mutations (missense muta-
tions) or small (from 1 to 3 nucleotides) insertions 
or deletions. It is important that single mutations 
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occur at different frequencies and influence, in 
various ways, the activity of the KatG protein. 
The phenotypic effect of mutations, i.e. changed 
enzymatic activity of KatG, is evaluated in the in 
vitro tests. 
The purpose of this study was to investigate 
the occurrence of mutations in the katG gene of 
multidrug-resistant M. tuberculosis clinical isolates 
recovered from MDR-TB patients in Poland in 2004.
Material and methods
Bacterial strains
The study included 46 strains of M. tuberculo-
sis, which are part of the collection of the Depart-
ment of Microbiology of the National Tuberculosis 
and Lung Diseases Research Institute in Warsaw. 
The strains were isolated from 46 Polish patients, 
diagnosed with TB in 20 medical facilities located 
in 11 provinces, and from whom MDR M. tuber-
culosis were cultured during the 12 months from 
January 1st to December 31st, 2004.
The culture of mycobacterial strains was 
done using a conventional method on Löwenstein- 
-Jensen (L.-J.) medium [13].
Species identification was performed with the 
help of the niacin test, NAP test (the Bactec 460-Tb 
system), genetic probe AccuProbe (Gen-Probe), 
ProbeTec (Becton-Dickinson) and the analysis of 
mycolic acids by high pressure liquid chromato-
graphy (Varian).
Drug susceptibility testing
Drug susceptibility of M. tuberculosis strains 
was determined in subculture on L.-J. medium, in 
accordance with the methodology applied in all 
mycobacteria laboratories in Poland. Briefly, the 
following drug concentrations were used: 0.2 μg/ 
/mL for INH, 40 μg/mL for RMP, 4 μg/mL for strep-
tomycin (SM) and 2 μg/mL for ethambutol (EMB). 
The strains whose growth was at least 1% of that 
on drug-free medium, and with resistance ratio 
(RR) at least four times higher in relation to the 
reference strain H37Rv (RR ≥ 4), were recognized 
as resistant [13].
To determine the minimal inhibitory concen-
tration (MIC) of INH for the studied strains, a series 
of 10 different concentrations, i.e. 0.2, 0.5, 1, 2.5, 
5, 10, 20, 40, 80 and 100 μg/mL was used.
Catalase activity
The catalase activity of M. tuberculosis strains 
was determined semi-quantitatively using the Ku-
bica method [14]. The catalase activity was expres-
sed as the height of the foam column (h), measured 
in millimetres. The following scale was used: h ≤ 5, 
negative reaction; h > 5, positive reaction; h > 45, 
strongly positive reaction.
DNA isolation
Isolation of chromosomal DNA of mycobac-
teria was conducted from the culture on L.-J. 
medium, according to the method using cetyltri-
methylammonium bromide (CTAB) [15].
Detection of mutations in the katG gene
Mutations in the katG gene were detected by 
sequencing the entire gene, obtained as a result 
of amplification performed by PCR method, as 
described by Cardoso et al. [16].
Amplification of the katG gene (2,223 pz) was 
performed in 4 PCR assays (A-D), with the primers, 
using the following scheme: 1. KatG-1-KatG-5 (A); 
2. KatG-4-KatG-9 (B); 3. KatG-8-KatG-13 (C); 4. 
KatG-12-KatG-14 (D) (Tab. 1).
Reaction mixtures were prepared by using 
a TopTaq MasterMix (Qiagen). The mixture of 
a final volume of 50 μL contained: 25 μL 2x TopTaq 
MasterMix (final concentration 1x), 0.5 μL of each 
primer (final concentration 0.2 μM), 22 μL of water 
and 2 μL of template genomic DNA (earlier dilu-
ted with water in a ratio of 1:50). The following 
PCR conditions were used: 95°C for 5 min (initial 
denaturation), followed by 35 cycles of: 95°C for 
30 s, 68°C or 62°C (only in amplification with 
primers KatG-12-KatG-14) for 30 s and 72°C for 
1 min. The final elongation step was performed 
at a temperature of 72°C for 7 min.
Homogeneity of PCR products was assessed 
electrophoretically. Electrophoresis was conduc-
ted in 1.5% agarose gels in TBE buffer. The gels 
were stained with ethidium bromide (0.5 μg/mL), 
and the DNA was visualized under UV light. The 
gel images were captured and analysed using 
ImageMaster® VDS (Video Documentation System) 
software (Amersham Pharmacia Biotech.). 
The obtained PCR products were purified by 
using a PCR “Clean Up” kit (A&A, Biotechnology), 
according to the manufacturer’s instructions.
The purified PCR products of at least 10 ng/ 
/μL concentration were sequenced by using the 
ABI PRISM 310 analyser (Applied Biosystems, 
CA, USA). Sequencing was performed in both 
forward and reverse directions (i.e. 5’Æ3’ and 
3’Æ5’). Sequencing was done with the help of the 
same primers used for thePCR amplification of the 
katG gene (Tab. 1).
Analysis of the obtained nucleotide sequences 
was conducted using Chromas 1.45 software and 
programs from the EMBOSS package (Matcher, 
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Table 1. Primers used for PCR amplification and sequencing of the katG gene of M. tuberculosis and their basic characteristics
Primer  
designation
Sequence
(5’ Æ 3’)
Location (bp)b Ta 
(°C)c
PCR product size
(bp)
X68081a KatG–1 GCCCGATAACACCAACTCCTG 1947–2606 68 680
KatG–5 CAGATCCCGCTACCGCTGTA
KatG–4 CCTGGCTCGGCGATGA
2586–3213 68 648KatG–9 CTCGGTGGATCAGCTTGTACC
KatG–8 GAGGAATTGGCCGACGAGTT
3182–3828 68 667KatG–13 TCTCAGGGGCACTGAGCGTAA
KatG–12 GCCGAGTACATGCTGCTCGAC
3794–4229 62 452KatG–14 CGGCGGGTTGTGGTTGA
aGenBank accession number for the M. tuberculosis H37Rv katG gene 
bPositioning of the primers; Numbers refer to the nucleotide position within the referenced GenBank sequence (X68081) 
cAnnealing temperature of the primers
Revseq, Transeq). Sequences were analysed by 
comparing with the wild-type katG gene sequence 
originating from the M. tuberculosis H37Rv referen-
ce strain available in GenBank (GenBank accession 
number: X68081).
Results
The occurrence of mutations in the katG gene 
in 46 MDR-resistant M. tuberculosis strains with 
different resistance levels to INH and different 
catalase activity was investigated.
Electrophoretic separation of 4 products of 
the katG gene amplification revealed, for each of 
the studied strains, the presence of a single DNA 
band of an expected size of 680, 648, 667 and 
452 bp, for the katG gene fragments amplified by 
using primers KatG-1-KatG-5 (A), KatG-4-KatG-9 
(B), KatG-8-KatG-13 (C) and KatG-12-KatG-14 (D), 
respectively (Fig. 1).
Among the 46 examined M. tuberculosis stra-
ins, mutations in the katG gene were found in 43 
strains (93%). Three strains did not show any mu-
tation in the katG gene sequence (Tab. 2). Among 
strains with an altered katG gene sequence, 34 
(74%) had mutations at nucleotide position 944; 
in 32 strains (69%) it was transition GÆC, in 1 
strain (no. 4832) it was transversion GÆT, and in 
one strain (no. 1377) it was transversion GÆA. 
Mutations other than those at position 944 were 
rare. Mutation at position 1388 (GÆT) was found in 
4 strains (nos. K131, 3430, 3020 and 1334). Mutation 
at position 392 was found in 2 strains; in one case 
it was transition CÆG (strain no. 101), in another - 
transversion CÆA (535). In two strains (nos. 11420 
and 12489) mutation at position 945, being a tran-
sversion CÆT was found. In another two strains 
(nos. 590 and 5895) mutation at position 701 (CÆG) 
was discovered. Furthermore, substitutions were 
found in single strains at the following positions: 
203 (TÆG) (strain no. 590), 271 (TÆC) (4991), 302 
(TÆC) (2497), 378 (GÆA) (103), 383 (GÆA) (4619), 
580 (GÆT) (101) and 1360 (GÆT) (590).
All discovered mutations were point muta-
tions and relied on substitution of individual nuc-
leotides. Only one strain (no. 5895) had a mutation 
which was an insertion of thymine at position 135 
(insT135).
As for the number of mutations per individu-
al strains, 35 strains (76%) had single mutations 
in the katG gene, whereas 8 (17%) had one or 
two additional mutations. More precisely, 3 stra-
ins had, apart from a mutation at position 944, 
a change at position 1388 (strains nos. K131, 3430, 
1334), 2 strains had mutations at positions 944 
and at position 945 (11420, 12489), one strain had 
mutations at positions 392 and 580 (no. 101), and 
another strain (5895) — at positions 135 and 701. 
Only one strain (no. 590) had 3 mutations, i.e. at 
positions 203, 701 and 1360.
Among the 16 different changes at the nuc-
leotide sequence level, 14 resulted in amino acid 
substitution in the polypeptide chain of KatG (Fig. 2). 
It concerned mainly codon 315 (34 tested strains 
(74%)) resulting in 94% of the strains (32 strains), 
in substitution SerÆThr. At the nucleotide sequ-
ence level it concerned AGCÆACC substitution for 
30 strains (88% of strains with mutation at this codon) 
or AGCÆACT substitution for 2 strains. Two other 
mutations at codon 315 were changes SerÆAsn 
(AGCÆAAC) and SerÆIle (AGCÆATC), both found 
in single strains. The ArgÆLeu (CGGÆCTG) sub-
stitution within the KatG codon 463 was observed 
in 4 strains (9%). In two cases there was a change 
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Figure 1. Products of the amplification of the entire katG gene in 4 PCR assays (A–D) generated for two selected M. tuberculosis strains 
(nos. 590 and 5895); MW, molecular weight marker (PerfectTM 100 bp DNA Ladder, EURx)
680 pz
590 5895
MW A B C D A B C D MW
1000
500
[pz]
1000
500
[pz]
667 pz648 pz680 pz
452 pz452 pz
667 pz648 pz
in codon 131: in the first case it was ProÆGln 
(CCGÆCAG) and in the second — ProÆArg (CC-
GÆCGG). The substitution AlaÆGly (GCGÆGGG) 
within the KatG codon 234 was noted in the next 
two strains. In the remaining cases only single 
mutations were present: Val68Gly (GTGÆGGG), 
Trp91Arg (TGGÆCGG), Leu101Pro (CTGÆCCG), 
Met126Ile (ATGÆATA), Arg128Gln (CGGÆCAG) 
and Asp194Tyr (GATÆTAT).
Among the 43 strains in which mutations in 
the katG gene sequence occurred, in 41 (95%) stra-
ins the mutations led to amino acid substitutions in 
the KatG peptide chain (the missense mutations). In 
2 strains single nonsense mutations were demon-
strated. By introducing unique translation termi-
nation codons (STOP), these mutations resulted in 
polypeptide truncation. While transversion GÆT 
at position 1360 generated codon STOP (TAG) 
at position 454 of the amino acid sequence, an 
insertion of thymine at position 135 (insT135) 
generated a frameshift mutation and produced 
termination codon (TAA) at protein position 46. 
As a result of the described mutations, catalase 
polypeptide was shortened by 287 and 695 amino 
acid residues, accordingly, as compared to the 
wild-type protein (740 amino acids).
Thirty-seven (80%) strains had single substitu-
tions in the amino acid sequence of the KatG. Six 
(13%) strains had additional changes: in 3 cases next 
to the change Ser315Thr, substitution Arg463Leu 
(strains nos. K131, 3430, 1334) was found; a change 
being a substitution Ala234Gly and another intro-
ducing codon STOP (5895) were discovered in one 
strain, whereas changes Pro131Arg and Asp194Tyr 
(101) were found in another strain. One strain 
(no. 590) had 3 different changes: Val68Gly, Ala-
234Gly and Glu454STOP.
Among the 43 strains with mutations within 
the katG gene, thirty-six (84%) retained catalase 
activity (Tab. 2). In the group of strains without mu-
tations, catalase reaction was positive in 2 strains 
(nos. 6679 and 11844), whereas in the case of one 
strain (73) the reaction was negative. Thirty-two 
(94%) out of 34 strains with mutations associa-
ted with codon 315 showed catalase activity: in 
20 strains the catalase reaction was positive, and 
in 12 strains it was strongly positive. Two strains 
(nos. 1114 and 647) showed no catalase activity.
The MIC values for INH in strains with mu-
tations in the katG gene were within the range of 
the following concentrations: 0.1 μg/mL ≤ MIC ≤ 
100 μg/mL. The MICs for INH of strains with a wild-
-type version of of the katG gene were 1 μg/mL for 
2 strains (nos. 6679 and 11844) and 10 μg/mL for one 
strain (no. 73). The MICs for strains with mutations 
at codon 315 ranged as follows: 1 ≤ MIC ≤ 10 μg/mL. 
For the majority of these strains (26 strains, 76%) the 
MIC value of INH was 2.5 μg/mL (Tab. 2).
Discussion
According to different studies, mutations in 
the katG gene occur in 50-95% of INH-resistant 
strains [11, 12, 16–19]. The most commonly ob-
served mutations in locus katG are substitutions 
at codon 315. The most frequent is transition GÆC 
(AGCÆACC), resulting in the replacement of se-
rine with threonine (SerÆThr) in the amino acid 
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Figure 2. Schematic representation of the katG gene mutations identified among 46 multidrug-resistant M. tuberculosis strains, evaluated in this study. 
Nucleotide alleles and corresponding amino acid alleles at which mutations occurred are indicated by their codon positions in light grey boxes at the 
top and bottom of the figure, respectively. Number and percentage of strains bearing the specific mutation are given in brackets
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Table 2.  Mutations in the katG gene, identified among 46 multidrug-resistant M. tuberculosis strains and their selected 
phenotypic characteristics
No. Strain 
no.
Drug resistance profilea MICINH
[μgxml–1]
Catalase 
activityb
Changes identified atc:
Nucleotide level Amino acid level
1. 101 INH+RMP 1 > 45 C Æ G (392) 
G Æ T (580)
Pro Æ Arg (131) 
Asp Æ Tyr (194)
2 124 SM+INH+RMP+EMB 2.5 34 G Æ C (944) Ser Æ Thr (315)
3. 4991 INH+RMP+EMB 1 3 T Æ C (271) Trp Æ Arg (91)
4. 1334 SM+INH+RMP 2.5 > 45 G Æ C (944) 
G Æ T (1388)
Ser Æ Thr (315) 
Arg Æ Leu (463)
5. 9310 SM+INH+RMP 1 7 G Æ C (944) Ser Æ Thr (315)
6. 2497 SM+INH+RMP 0.1 > 45 T Æ C (302) Leu Æ Pro (101)
7. 4619 SM+INH+RMP+EMB 0.5 > 45 G Æ A (383) Arg Æ Gln (128)
8. 4202 SM+INH+RMP 2.5 11 G Æ C (944) Ser Æ Thr (315)
9. 4365 SM+INH+RMP 2.5 > 45 G Æ C (944) Ser Æ Thr (315)
10. 3312 SM+INH+RMP 2.5 > 45 G Æ C (944) Ser Æ Thr (315)
11. 1885 SM+INH+RMP 2.5 26 G Æ C (944) Ser Æ Thr (315)
12. 5325 SM+INH+RMP+EMB 2.5 > 45 G Æ C (944) Ser Æ Thr (315)
13. 794 SM+INH+RMP 2.5 34 G Æ C (944) Ser Æ Thr (315)
14. 692 SM+INH+RMP 2.5 8 G Æ C (944) Ser Æ Thr (315)
15. 6679 SM+INH+RMP+EMB 1 6 – –
16. 535 INH+RMP 1 4 C Æ A (392) Pro Æ Gln (131)
17. 874 SM+INH+RMP 2.5 11 G Æ C (944) Ser Æ Thr (315)
18. 434 SM+INH+RMP 2.5 > 45 G Æ C (944) Ser Æ Thr (315)
19. 469 INH+RMP 10 10 G Æ C (944) Ser Æ Thr (315)
20. 3832 SM+INH+RMP+EMB 2.5 > 45 G Æ C (944) Ser Æ Thr (315)
21. 524 SM+INH+RMP 2.5 27 G Æ C (944) Ser Æ Thr (315)
22. 590 SM+INH+RMP 100 0 T Æ G (203) 
C Æ G (701) 
G Æ T (1360)
Val Æ Gly (68) 
Ala Æ Gly (234) 
STOP (454)
23. 12489 SM+INH+RMP 1 27 G Æ C (944) 
C Æ T (945)
Ser Æ Thr (315)
24. 11420 INH+RMP 1 32 G Æ C (944) 
C Æ T (945)
Ser Æ Thr (315)
25. 2575 INH+RMP 2.5 8 G Æ C (944) Ser Æ Thr (315)
26. 456 INH+RMP 2.5 22 G Æ C (944) Ser Æ Thr (315)
27. 1114 INH+RMP 2.5 3 G Æ C (944) Ser Æ Thr (315)
28. 1377 SM+INH+RMP 2.5 > 45 G Æ A (944) Ser Æ Asn (315)
29. 17170 INH+RMP 2.5 10 G Æ C (944) Ser Æ Thr (315)
30. 2688 INH+RMP 2.5 > 45 G Æ C (944) Ser Æ Thr (315)
31. 947 INH+RMP 2.5 > 45 G Æ C (944) Ser Æ Thr (315)
32. 3298 SM+INH+RMP 1 19 G Æ C (944) Ser Æ Thr (315)
33. 11844 SM+INH+RMP 1 16 – –
34. 2233 SM+INH+RMP+EMB 2.5 16 G Æ C (944) Ser Æ Thr (315)
35. 3020 SM+INH+RMP+EMB 2.5 43 G Æ T (1388) Arg Æ Leu (463)
36. 3430 SM+INH+RMP 2.5 10 G Æ C (944) 
G Æ T (1388)
Ser Æ Thr (315) 
Arg Æ Leu (463)
Æ
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37. K131 SM+INH+RMP 10 37 G Æ C (944) 
G Æ T (1388)
Ser Æ Thr (315) 
Arg Æ Leu (463)
38. 1233 INH+RMP 2.5 >45 G Æ C (944) Ser Æ Thr (315)
39. 5895 INH+RMP 80 0 insT (135) 
C Æ G (701)
STOP (46) 
Ala Æ Gly (234)
40. 446 SM+INH+RMP 2.5 17 G Æ C (944) Ser Æ Thr (315)
41. 2086 SM+INH+RMP 2.5 > 45 G Æ C (944) Ser Æ Thr (315)
42. 103 SM+INH+RMP 2.5 4 G Æ A (378) Met Æ Ile (126)
43. 1612 SM+INH+RMP 2.5 > 45 G Æ C (944) Ser Æ Thr (315)
44. 4832 SM+INH+RMP 10 18 G Æ T (944) Ser Æ Ile (315)
45. 73 INH+RMP+EMB 10 2 – –
46. 647 INH+RMP 5 3 G Æ C (944) Ser Æ Thr (315)
a INH, isoniazid; RMP, rifampicin; SM, streptomycin; EMB, ethambutol 
b Catalase activity according to Kubica test, measured (in millimetres) as the height of the foam column 
c Nucleotide or amino acid positions are given in brackets
Table 2. continuation
chain. Much more unusual are other nucleotide 
substitutions generating codons: ACA (Thr), ATC 
(Ile), AGA (Arg), AGG (Arg), CGC (Arg), AAC (Asn) 
and GGC (Gly) [11, 12, 16, 18–31]. The frequen-
cy at which mutations at codon 315 of the katG 
gene occur differs between geographical regions. 
Such mutations have been discovered in 97% of 
INH-resistant strains isolated in South Africa [32], 
86–94% of strains isolated in Russia, Lithuania and 
Latvia [24, 33, 34], 60-87% in Brazil [16, 35], about 
65% in Australia, China and Kuwait [12, 22, 27], 
53% in the Netherlands [36], 46% in Spain [37] and 
38% in Italy [38]. A relatively small proportion of 
mutations at codon 315 have been noted in INH-re-
sistant strains obtained from patients from Japan 
(28%) [21], even lower from patients from Finland 
(7%) [32], and the lowest from South Korea and the 
United States (4%) [39]. Pretorius et al. described 
39 INH-resistant strains isolated from patients from 
South Africa, the United States and Switzerland, 
all of which had an unchanged (wild-type) version 
of the katG gene [40].
Thus far there have been only two studies on 
genetic determination of INH resistance in M. tu-
berculosis strains from Poland. Molecular analysis 
conducted by Sajduda et al. has shown that 55 (66%) 
out of 83 INH-resistant strains had mutations at 
codon 315 within the katG gene. Fifty (90%) strains 
had the most frequent mutation AGCÆACC [41]. In 
another study, Wojtyczka et al., while investigating 
the occurrence of mutation Ser315Thr among 23 
INH-resistant strains (including 6 MDR strains) 
isolated from patients from Silesia, found it only in 
2 strains (9%) (including 1 MDR strain) [42].
In this study, the presence of mutation at co-
don 315 was found in 34 (74%) out of 46 MDR-TB 
strains (for 32 strains it was mutation Ser315Thr, 
which in case of 30 strains was a AGCÆACC sub-
stitution).
All but 2 strains (32; 94%) with mutation at 
codon 315 were catalase-positive, which indicates 
that this type of mutation does not adversely in-
fluence the enzymatic activity of the KatG protein. 
Similarly, studies by other authors have proved 
that the majority of INH-resistant strains with 
mutations at codon 315 retained their catalase 
activity [11, 17, 18, 20] (differences in the level of 
the enzymatic activity that occur between these 
strains may be a result, for example, of the presence 
of additional mutations in the katG gene). In order 
to find the physiological role of the mutation at 
codon 315, Wengenack et al. compared the enzy-
matic activity of the wild-type protein KatG with 
the KatG protein bearing a single Ser315Thr mu-
tation [43]. They showed that the mutated protein 
retained significant catalase activity while showing 
a lowered ability to activate INH. The loss of the 
ability to metabolize INH is due to the fact that 
mutation Ser315Thr changes the stereochemical 
structure of the protein that decreases its affinity 
to the drug [44]. Furthermore, as it has been proven 
on a mouse model that the virulence of the katG 
Ser315Thr mutants is similar to that observed in 
wild-type strains [45]. Analysis of the phenotype 
of M. tuberculosis strains with the katG Ser315Thr 
mutation shows explicitly that it is physiologically 
profitable. The high prevalence of this mutation 
among INH-resistant strains may be attributed to 
the positive selective pressure.
A number of studies have shown that the 
presence of a mutation at codon 315 in the katG 
gene is often associated with a high level of INH 
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resistance (MIC ≥ 4 μg/mL) [12, 16, 17, 25, 35, 36]. 
This correlation was confirmed only partially by 
the results of the present study. All strains with 
mutations at codon 315 had their MIC values 
for INH within the range of 1–10 μg/mL. For the 
majority of these strains (26, 76%) the MIC value 
was 2.5 μg/mL. 
Among the strains in which mutations at 
codon 315 were absent, 2 strains had the highest 
level of INH resistance (MIC = 80 and 100 μg/ml). 
These strains were also the only ones for which 
the catalase reaction was entirely negative (h = 0). 
In the katG sequence of these two strains the pre-
sence of single nonsense mutations (Lys46STOP, 
Glu454STOP) was reported. These mutations led to 
catalase polypeptide truncation and thus abolished 
its enzymatic activity. It is plausible that the lack 
of functional KatG also conditioned a particularly 
high resistance to INH in those strains, as can be 
seen in the case of katG gene deletion [9–12]. 
Many authors emphasize the usefulness of 
the analysis of mutation at codon 315 (mainly Ser-
315Thr) in the katG gene for detecting resistance 
to INH in M. tuberculosis. The diagnostic value of 
such analysis is particularly important in countries 
with high TB prevalence and high TB transmission 
rate of drug-resistant M. tuberculosis strains. Here, 
mutations at codon 315 occur in more than 90% of 
INH-resistant strains [32–34, 46]. However, in co-
untries where the frequency of mutations at codon 
315 is significantly lower, the usefulness of  finding 
such mutations such mutations for the detection 
of INH resistance is rather limited. Although mu-
tations at codon 315 within the katG gene occur 
only in some MDR M. tuberculosis strains, which 
was confirmed by the present study (such muta-
tions were absent in a quarter of the studied MDR- 
-resistant strains), examination of their occur-
rence may serve as a rapid screening test for 
drug resistance. Such an approach is justified by 
the fact that the above mensioned mutations are 
100% specific for INH-resistant strains, and their 
identification takes significantly less time than 
determination of drug resistance using a conven-
tional method. Amplification techniques used for 
detecting mutations associated with drug resistan-
ce do not require the growth of mycobacteria and 
may be applied directly to clinical specimens [47].
A fast screening test for mutations at codon 
315 may be of great significance for detection 
of MDR resistance. According to many authors, 
mutations at codon 315 in the katG gene occur 
more frequently in MDR strains than in the INH- 
-monoresistant strains [24, 26, 36, 48]. Additionally, 
78–94% of MDR tubercle bacilli harbour these 
mutations [24, 31, 34, 46]. One of the hypotheses 
explaining this phenomenon assumes that muta-
tions within katG codon 315 increase the fitness 
of mycobacteria, thus strengthening their ability 
to survive in the human host, be transmitted, and 
develop complex drug resistance patterns [26]. 
This hypothesis has recently been supported by the 
studies of van Doorn et al. from the Netherlands 
[49] and Gagneux et al. from San Francisco [50], 
who demonstrated that INH-resistant M. tuberculo-
sis strains with mutations at codon 315 (especially 
Ser315Thr mutation) are more frequently involved 
in recent TB transmission than other INH-resistant 
strains without this mutation.
Conclusions
Mutations in the katG gene were found in 43 
(93%) of the MDR M. tuberculosis strains tested. 
The most frequent mutation was substitution at 
codon 315, which was demonstrated in 34 (74%) 
strains. The presence of mutations at this codon 
may serve as a predictive factor for INH resistance.
Among the 16 different mutations discove-
red at the level of the katG nucleotide sequence, 
14 (87.5%) resulted in the amino acid change in the 
KatG polypeptide chain (the missense mutations). 
In the case of 2 strains, single nonsense mutations 
were disclosed. By introducing unique transla-
tion termination codons, they led to polypeptide 
truncation.
While the missense mutations did not influence 
catalase activity or the level of INH resistance, the 
nonsense mutations resulted in a high level of INH 
resistance and a complete loss of catalase activity.
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